Loading
GeneCraft is a Korean company testing a gene therapy, injected into the tumour, that restores a natural defence gene called RUNX3 to kill lung cancer cells driven by faulty KRAS.
GeneCraft Inc., headquartered at Chungbuk National University in Cheongju with an R&D centre in Seoul, develops gene therapies built on the tumour-suppressor research of its founder and co-CEO Suk-Chul Bae on RUNX3. Its lead programme RX001 (AAV-hRUNX3), made on its Ubi-AAV platform, is designed to selectively kill KRAS-mutated cancer cells; a phase 1 dose-escalation study gives a single intratumoral injection to patients with advanced KRAS-mutant non-small cell lung cancer (NCT06934590). Its first registered cancer trial, NCT06934590, was posted on ClinicalTrials.gov in April 2025.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/